Literature DB >> 24578237

Best practices for the development, scale-up, and post-approval change control of IR and MR dosage forms in the current quality-by-design paradigm.

Glenn A Van Buskirk1, Satish Asotra, Christopher Balducci, Prabir Basu, Gerald DiDonato, Angelica Dorantes, W Mark Eickhoff, Tapash Ghosh, Mario A González, Theresa Henry, Matthew Howard, Jason Kamm, Steven Laurenz, Ryan MacKenzie, Richard Mannion, Patrick K Noonan, Terrance Ocheltree, Umesh Pai, Richard P Poska, Michael L Putnam, Ramani R Raghavan, Colleen Ruegger, Eric Sánchez, Vinod P Shah, Zezhi Jesse Shao, Russell Somma, Vijay Tammara, Avinash G Thombre, Bruce Thompson, Robert J Timko, Satyam Upadrashta, Sivakumar Vaithiyalingam.   

Abstract

In this whitepaper, the Manufacturing Technical Committee of the Product Quality Research Institute provides information on the common, best practices in use today in the development of high-quality chemistry, manufacturing and controls documentation. Important topics reviewed include International Conference on Harmonization, in vitro-in vivo correlation considerations, quality-by-design approaches, process analytical technologies and current scale-up, and process control and validation practices. It is the hope and intent that this whitepaper will engender expanded dialog on this important subject by the pharmaceutical industry and its regulatory bodies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24578237      PMCID: PMC4037495          DOI: 10.1208/s12249-014-0087-x

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  4 in total

1.  Quality by design: concepts for ANDAs.

Authors:  Robert A Lionberger; Sau Lawrence Lee; Laiming Lee; Andre Raw; Lawrence X Yu
Journal:  AAPS J       Date:  2008-05-09       Impact factor: 4.009

2.  Scaleup of oral extended-release dosage forms.

Authors:  J P Skelly; G A Van Buskirk; H M Arbit; G L Amidon; L Augsburger; W H Barr; S Berge; J Clevenger; S Dighe; M Fawzi
Journal:  Pharm Res       Date:  1993-12       Impact factor: 4.200

3.  Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations.

Authors:  H Malinowski; P Marroum; V R Uppoor; W Gillespie; H Y Ahn; P Lockwood; J Henderson; R Baweja; M Hossain; N Fleischer; L Tillman; A Hussain; V Shah; A Dorantes; R Zhu; H Sun; K Kumi; S Machado; V Tammara; T E Ong-Chen; H Mahayni; L Lesko; R Williams
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

4.  Scaleup of immediate release oral solid dosage forms.

Authors:  J P Skelly; G A Van Buskirk; D R Savello; G L Amidon; H M Arbit; S Dighe; M B Fawzi; M A Gonzalez; A W Malick; H Malinowski
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

  4 in total
  1 in total

1.  Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks.

Authors:  Jeremy A Bartlett; Marcus Brewster; Paul Brown; Donna Cabral-Lilly; Celia N Cruz; Raymond David; W Mark Eickhoff; Sabine Haubenreisser; Abigail Jacobs; Frank Malinoski; Elaine Morefield; Ritu Nalubola; Robert K Prud'homme; Nakissa Sadrieh; Christie M Sayes; Hripsime Shahbazian; Nanda Subbarao; Lawrence Tamarkin; Katherine Tyner; Rajendra Uppoor; Margaret Whittaker-Caulk; William Zamboni
Journal:  AAPS J       Date:  2014-11-25       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.